Live tape
Top 8, mentions 7d9,701TSLA2,115 mentions▲ +0.05GOOGL1,358 mentions▲ +0.04CRWV1,306 mentions▲ +0.03SPCX1,152 mentions▲ +0.07NVDA1,130 mentions▲ +0.07QQQ1,034 mentions▲ +0.05NBIS843 mentions▲ +0.06META763 mentions▲ +0.05

Equity · Healthcare

ZLAB

NASDAQ

Zai Lab Limited

$20 −3.66% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for ZLAB to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $22.2B
52-week range $16.32 – $40.56
Avg volume 216.8K

as of Jul 17, 2026

ZLAB insider trades

SEC Form 4 · last 90 days · newest reported trade 19 Aug 2026
Open-market buys 0
Open-market sells 3
Net sold $235K
Non-trade filings 4
Date Insider Type Shares Value
19 Aug 2026 Chen Yajing Chief Financial Officer Sell 260 $7K
12 Aug 2026 Lis William Director Sell 8,506 $213K
11 Aug 2026 Chen Yajing Chief Financial Officer Sell 619 $15K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Oct 2026 Chen Yajing Chief Financial Officer Option exercise 920
01 Oct 2026 Chen Yajing Chief Financial Officer Tax withheld 315 $8K
14 Aug 2026 Chen Yajing Chief Financial Officer Option exercise 1,250
14 Aug 2026 Chen Yajing Chief Financial Officer Tax withheld 427 $11K

ZLAB reported financials

SEC EDGAR XBRL SEC EDGAR

ZLAB reported revenue of $457.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$175.5M.

Figure Reported Period
Revenue $457.2M 31 Dec 2025 fiscal year
Net income −$175.5M 31 Dec 2025 fiscal year
Diluted EPS −$0.16 31 Dec 2025 fiscal year
Total assets $1.1B 30 Jun 2026 at period end
Total equity $607.0M 30 Jun 2026 at period end

ZLAB earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.05 $106M
31 Mar 2026 Q1 2026 −$0.05 $100M
31 Dec 2025 FY 2025 −$0.16 $460M
30 Sep 2025 Q3 2025 −$0.03 $116M
30 Jun 2025 Q2 2025 −$0.04 $110M
31 Mar 2025 Q1 2025 −$0.04 $106M
31 Dec 2024 FY 2024 −$0.26 $399M
30 Sep 2024 Q3 2024 −$0.04 $102M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ZLAB institutional holders

SEC Form 13F SEC EDGAR

4 of the 45 institutional funds we track reported a ZLAB position for the quarter ended 30 Jun 2026 — a combined $54.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Added +319.5% shares 1,299,394 $24.7M
Citadel Advisors Held (±25%) −23.9% shares 1,284,706 $24.4M
Marshall Wace New position 147,217 $2.8M
D. E. Shaw & Co. Added +123.2% shares 141,158 $2.7M
Point72 Asset Management Exited
Renaissance Technologies Exited

ZLAB fails-to-deliver

SEC CNS data SEC

On 25 Sep 2026, 4,000 shares of ZLAB failed to deliver (about $101K) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
25 Sep 2026 4,000 $101K <0.001%
24 Sep 2026 17,832 $471K 0.002%
21 Sep 2026 1,344 $35K <0.001%
14 Sep 2026 4,740 $114K <0.001%
11 Sep 2026 2,240 $54K <0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings